SENSEX NIFTY

Bsufa

Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

Photos »

  /  
USFDA to review Biocon-Mylan's biosimilar drug for breast cancer
Messages on Bsufa »

koppik

Gold Member

11 Followers

Biocon  

Gives visibility with goal date under the Biosimilar User Fee Act (BsUFA) of September 03, 2017!

7.47 PM Jan 11th

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.